224 related articles for article (PubMed ID: 25519488)
1. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
Shah RR; Smith RL
Drug Metab Dispos; 2015 Mar; 43(3):400-10. PubMed ID: 25519488
[TBL] [Abstract][Full Text] [Related]
2. Addressing phenoconversion: the Achilles' heel of personalized medicine.
Shah RR; Smith RL
Br J Clin Pharmacol; 2015 Feb; 79(2):222-40. PubMed ID: 24913012
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
4. To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population.
De Andrés F; Terán S; Hernández F; Terán E; LLerena A
OMICS; 2016 Dec; 20(12):699-710. PubMed ID: 27849442
[TBL] [Abstract][Full Text] [Related]
5. Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity.
Darakjian L; Deodhar M; Turgeon J; Michaud V
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34067027
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.
Nahid NA; Johnson JA
Expert Opin Drug Metab Toxicol; 2022 Nov; 18(11):769-785. PubMed ID: 36597259
[TBL] [Abstract][Full Text] [Related]
7. Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics.
de Jong LM; Jiskoot W; Swen JJ; Manson ML
Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33339226
[TBL] [Abstract][Full Text] [Related]
8. How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial.
Cicali EJ; Elchynski AL; Cook KJ; Houder JT; Thomas CD; Smith DM; Elsey A; Johnson JA; Cavallari LH; Wiisanen K
Clin Pharmacol Ther; 2021 Sep; 110(3):677-687. PubMed ID: 34231197
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.
Sim SC; Kacevska M; Ingelman-Sundberg M
Pharmacogenomics J; 2013 Feb; 13(1):1-11. PubMed ID: 23089672
[TBL] [Abstract][Full Text] [Related]
10. The Evaluation of
Giorgetti A; Amurri S; Fazio G; Bini C; Anniballi L; Pirani F; Pelletti G; Pelotti S
Metabolites; 2023 May; 13(5):. PubMed ID: 37233702
[TBL] [Abstract][Full Text] [Related]
11. The impact of
de Jong LM; Boussallami S; Sánchez-López E; Giera M; Tushuizen ME; Hoekstra M; Hawinkels LJAC; Rissmann R; Swen JJ; Manson ML
Front Pharmacol; 2023; 14():1201906. PubMed ID: 37361233
[No Abstract] [Full Text] [Related]
12. CYP450 genotype and pharmacogenetic association studies: a critical appraisal.
Shah RR; Gaedigk A; LLerena A; Eichelbaum M; Stingl J; Smith RL
Pharmacogenomics; 2016 Feb; 17(3):259-75. PubMed ID: 26780308
[TBL] [Abstract][Full Text] [Related]
13. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
Prandota J
Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
[TBL] [Abstract][Full Text] [Related]
14. Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review.
Klomp SD; Manson ML; Guchelaar HJ; Swen JJ
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32906709
[TBL] [Abstract][Full Text] [Related]
15. Drug metabolic enzyme genotype-phenotype discrepancy: High phenoconversion rate in patients treated with antidepressants.
Gloor Y; Lloret-Linares C; Bosilkovska M; Perroud N; Richard-Lepouriel H; Aubry JM; Daali Y; Desmeules JA; Besson M
Biomed Pharmacother; 2022 Aug; 152():113202. PubMed ID: 35653884
[TBL] [Abstract][Full Text] [Related]
16. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression.
Temesvári M; Kóbori L; Paulik J; Sárváry E; Belic A; Monostory K
J Pharmacol Exp Ther; 2012 Apr; 341(1):294-305. PubMed ID: 22262920
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis of hepatic enzyme activities of drug metabolizing enzymes-phenotyping and genotyping].
Ozawa S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1999; (117):63-76. PubMed ID: 10859937
[TBL] [Abstract][Full Text] [Related]
18. [Study of the molecular mechanism of human cytochrome P450 and genetic polymorphism of drug oxidative metabolizing enzyme].
Zhao L; Lou YQ
Sheng Li Ke Xue Jin Zhan; 1997 Jan; 28(1):35-40. PubMed ID: 10921075
[TBL] [Abstract][Full Text] [Related]
19. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Molecular Perspectives on Inflammation-Mediated Regulation of Drug Metabolism and Transport.
Dunvald AD; Järvinen E; Mortensen C; Stage TB
Clin Pharmacol Ther; 2022 Aug; 112(2):277-290. PubMed ID: 34605009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
